Flow Traders U.S.’s Global X Genomics & Biotechnology ETF GNOM Stock Holding History

Flow Traders U.S.’s Portfolio GNOM Stock Details GNOM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-19,355	Closed	-$880K	–	1113
2025 Q4	$880K	Sell	19,355 -26,603	-58%	-$1.18M	0.03%	424
2025 Q3	$1.78M	Sell	45,958 -13,723	-23%	-$497K	0.07%	278
2025 Q2	$2.01M	Buy	59,681 +20,515	+52%	+$650K	0.07%	245
2025 Q1	$1.25M	Buy	39,166 +3,570	+10%	+$135K	0.05%	333
2024 Q4	$1.38M	Buy	35,596 +14,806	+71%	+$622K	0.06%	293
2024 Q3	$936K	Buy	+20,790	New	+$929K	0.05%	392
2021 Q3	–	Sell	-10,579	Closed	-$1.05M	–	1049
2021 Q2	$1.05M	Buy	10,579 +5,286	+100%	+$469K	0.05%	392
2021 Q1	$476K	Sell	5,293 -52	-1%	-$5.13K	0.03%	508
2020 Q4	$507K	Buy	+5,345	New	+$447K	0.03%	391

Other funds holding GNOM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Oppenheimer Asset Management New York $9.63B AUM 30.32% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

U.S. Capital Wealth Advisors Austin, Texas $3.98B AUM 22.36% 1-Year Est. Return

Stratos Wealth Partners Beachwood, Ohio $9.93B AUM 28.91% 1-Year Est. Return

Armis Advisers Atlanta, Georgia $1.2B AUM 15.74% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

CFD

Creative Financial Designs Kokomo, Indiana $2.1B AUM 23.1% 1-Year Est. Return

Flow Traders U.S.'s GNOM Position: Q1 2026 in Review

Flow Traders U.S. sold out of Global X Genomics & Biotechnology ETF (GNOM) in Q1 2026, closing a stake of 19,355 shares — an estimated $880K sold.

Flow Traders U.S. first reported a position in GNOM in Q4 2020 and held it in 9 quarters. The position peaked at $2.01M in Q2 2025. 40 funds tracked by Wall St. Rank hold GNOM as of Q1 2026.

Flow Traders U.S. reported no remaining Global X Genomics & Biotechnology ETF position as of Q1 2026 after selling out during the quarter.
Flow Traders U.S. sold 19,355 Global X Genomics & Biotechnology ETF shares in Q1 2026, an estimated $880K.
Flow Traders U.S. first reported a position in Global X Genomics & Biotechnology ETF in Q4 2020 and held it in 9 quarters.
Flow Traders U.S.'s Global X Genomics & Biotechnology ETF position peaked at $2.01M in Q2 2025.
40 funds tracked by Wall St. Rank held Global X Genomics & Biotechnology ETF as of Q1 2026.

Based on Flow Traders U.S.'s 13F filing for Q1 2026, filed 15 May 2026.